Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 11 Jul 2018 |
| Zealand announces amendments to its Articles of Association following the granting of warrants | 31 May 2018 |
| Zealand Pharma reports completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia | 28 May 2018 |
| Zealand grants new warrants under employee warrant program | 22 May 2018 |
| Zealand Pharma - Interim report for the first quarter of 2018 | 16 May 2018 |
| Zealand announces net sales of Soliqua® 100/33 and Lyxumia®/Adlyxin® for the first quarter of 2018 | 27 Apr 2018 |